Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials

Authors

P Barton Duell, Oregon Health and Science University
Maciej Banach, Medical University of Łódź
Alberico L Catapano, University of Milan
Ulrich Laufs, Universitätsklinikum Leipzig
G B John Mancini, University of British Columbia
Kausik K Ray, Imperial College London
Christine Broestl, Esperion Therapeutics, Inc.
Yang Zhang, Esperion Therapeutics, Inc.
Lei Lei, Esperion Therapeutics, Inc.
Anne C Goldberg, Washington University School of Medicine in St. Louis

Journal

Journal of Clinical Lipidology

Publication Date

1-1-2024

Volume

18

Issue

2

First Page

e153

Last Page

e165

Document Type

Open Access Publication

DOI

10.1016/j.jacl.2023.12.005

Rights and Permissions

Duell PB, Banach M, Catapano AL, Laufs U, Mancini GBJ, Ray KK, Broestl C, Zhang Y, Lei L, Goldberg AC. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials. J Clin Lipidol. 2024 Mar-Apr;18(2):e153-e165. doi: 10.1016/j.jacl.2023.12.005. © 2024 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Duell, P Barton; Banach, Maciej; Catapano, Alberico L; Laufs, Ulrich; Mancini, G B John; Ray, Kausik K; Broestl, Christine; Zhang, Yang; Lei, Lei; and Goldberg, Anne C, "Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials." Journal of Clinical Lipidology. 18, 2. e153 - e165. (2024).
https://digitalcommons.wustl.edu/oa_4/5320

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.